Share-based Payment Arrangement, Expense of Day One Biopharmaceuticals, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Day One Biopharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Day One Biopharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $11,068,000, a 0.3% increase year-over-year.
  • Day One Biopharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $44,388,000, a 8% decline year-over-year.
  • Day One Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $44,388,000, a 8% decline from 2024.
  • Day One Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $48,263,000, a 23% increase from 2023.
  • Day One Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $39,341,000, a 44% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Day One Biopharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $44,388,000 $11,068,000 +$33,000 +0.3% 01 Oct 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 $44,355,000 $9,561,000 -$1,993,000 -17% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $46,348,000 $10,898,000 -$2,132,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $48,480,000 $12,861,000 +$217,000 +1.7% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $48,263,000 $11,035,000 +$224,000 +2.1% 01 Oct 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 $48,039,000 $11,554,000 +$1,948,000 +20% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $46,091,000 $13,030,000 +$3,553,000 +37% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $42,538,000 $12,644,000 +$3,197,000 +34% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $39,341,000 $10,811,000 +$3,978,000 +58% 01 Oct 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
Q3 2023 $35,363,000 $9,606,000 +$1,030,000 +12% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $34,333,000 $9,477,000 +$3,846,000 +68% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $30,487,000 $9,447,000 +$3,245,000 +52% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $27,242,000 $6,833,000 +$1,736,000 +34% 01 Oct 2022 31 Dec 2022 10-K/A 06 Mar 2025 2024 FY
Q3 2022 $25,506,000 $8,576,000 +$3,427,000 +67% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $22,079,000 $5,631,000 +$3,094,000 +122% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $18,985,000 $6,202,000 +$5,664,000 +1053% 01 Jan 2022 31 Mar 2022 10-Q 01 May 2023 2023 Q1
Q4 2021 $13,321,000 $5,097,000 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $5,149,000 +$5,089,000 +8482% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $2,537,000 +$2,480,000 +4351% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $538,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $60,000 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $57,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2

Day One Biopharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $44,388,000 -$3,875,000 -8% 01 Jan 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
2024 $48,263,000 +$8,922,000 +23% 01 Jan 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
2023 $39,341,000 +$12,099,000 +44% 01 Jan 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
2022 $27,242,000 +$13,921,000 +105% 01 Jan 2022 31 Dec 2022 10-K/A 06 Mar 2025 2024 FY
2021 $13,321,000 +$12,795,000 +2433% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $526,000 +$415,000 +374% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 $111,000 01 Jan 2019 31 Dec 2019 10-K 07 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.